Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases.

Autor: Tong TML; Interventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Fiocco M; Mathematical Institute, Leiden University, Leiden, The Netherlands.; Medical Statistics Section, Department of Biomedical Data Science, Leiden University Medical Center, Leiden, The Netherlands., van Duijn-de Vreugd JJ; Interventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Lutjeboer J; Interventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Speetjens FM; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Tijl FGJ; Department of Extra Corporal Circulation, Leiden University Medical Center, Leiden, The Netherlands., Sitsen ME; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., Zoethout RWM; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., Martini CH; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., Vahrmeijer AL; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., van der Meer RW; Interventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., van Rijswijk CSP; Interventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., van Erkel AR; Interventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Burgmans MC; Interventional Radiology Research (IR2) Group, Department of Radiology, C2-S, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. M.C.Burgmans@lumc.nl.
Jazyk: angličtina
Zdroj: Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2024 Jun; Vol. 47 (6), pp. 741-750. Date of Electronic Publication: 2024 Apr 08.
DOI: 10.1007/s00270-024-03713-0
Abstrakt: Purpose: Percutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP.
Materials and Methods: A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver. QoL questionnaires were collected at baseline, on day 2/3 after M-PHP, and on day 7 and day 21 after M-PHP, according to study protocol. The results were scored according to EORTC-QLQ C30 global health status (GHS), functional scales, and symptom scales. The difference in scores at baseline and subsequent time points was analyzed with the Wilcoxon signed-rank test and multiple testing Bonferroni correction. Adverse events (AE) were registered up to 30 days after M-PHP according to CTCAE v5.0.
Results: Twenty-four patients (14 males; median age 63.0 years) completed 96 questionnaires. Most scores on all scales declined on day 2/3 after M-PHP. On day 21 after M-PHP, 12 out of 15 scores returned to baseline, including median GHS scores. Three variables were significantly worse on day 21 compared to baseline: fatigue (6-33; p = 0.002), physical functioning (100 vs 86.7; p = 0.003), and role functioning (100 vs 66.7; p = 0.001). Grade 3/4 AEs consisted mainly of hematological complications, such as leukopenia and thrombopenia.
Conclusion: M-PHP causes fatigue and a decline in physical and role functioning in the 1st weeks after treatment, but GHS returns to baseline levels within 21 days. LEVEL OF EVIDENCE 3: Cohort study.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: